In response to the global burden of severe RSV disease among infants, WHO recommends that all countries introduce either the ...

In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA ™ (clesrovimab-cfor), ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Respiratory syncytial virus (RSV) causes millions of childhood illnesses yearly, particularly in poorer countries. On 30 May 2025, the World Health Organisation issued its first global guidance ...

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the ...

As winter settles over Australia, it's not just the drop in temperature we notice—there's also a sharp rise in respiratory ...

It starts with a sniffle. A mild cough. You tell yourself it’s just a cold—babies get those, right? But make no mistake. RSV ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Many babies are heading into winter without full protection against the leading cause of severe respiratory illness in ...